SUVmax on FDG-PET is a predictor of prognosis in patients with maxillary sinus cancer

Springer Science and Business Media LLC - Tập 34 Số 5 - Trang 349-355 - 2016
Hiroshi Doi1, Kazuhiro Kitajima2, Kazuhito Fukushima2, Yusuke Kawanaka2, Miya Mouri2, Satoshi Yamamoto1, Reiichi Ishikura1, Tomonori Terada3, Kazuma Noguchi4, Shun Hirota1
1Department of Radiology, Hyogo College of Medicine, Nishinomiya, Japan
2Department of Nuclear Medicine and PET center, Hyogo College of Medicine, Nishinomiya, Japan
3Department of Otolaryngology, Hyogo College of Medicine, Nishinomiya, Japan
4Department of Oral and Maxillofacial Surgery, Hyogo College of Medicine, Nishinomiya, Japan

Tóm tắt

Từ khóa


Tài liệu tham khảo

Myers LL, Nussenbaum B, Bradford CR, Teknos TN, Esclamado RM, Wolf GT. Paranasal sinus malignancies: an 18-year single institution experience. Laryngoscope. 2002;112:1964–9.

Davies A, Tan C, Paschalides C, Barrington SF, O’Doherty M, Utley M, et al. FDG-PET maximum standardised uptake value is associated with variation in survival: analysis of 498 lung cancer patients. Lung Cancer. 2007;55:75–8.

Kato H, Nakajima M, Sohda M, Tanaka N, Inose T, Miyazaki T, et al. The clinical application of 18F-fluorodeoxyglucose positron emission tomography to predict survival in patients with operable esophageal cancer. Cancer. 2009;115:3196–203.

Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer. 2007;110:1738–44.

Xie P, Li M, Zhao H, Sun X, Fu Z, Yu J, et al. 18F-FDG PET or PET–CT to evaluate prognosis for head and neck cancer: a metaanalysis. J Cancer Res Clin Oncol. 2011;137:1085–93.

Muir CS, Nectoux J. Descriptive epidemiology of malignant neoplasms of nose, nasal cavities, middle ear and accessory sinuses. Clin Otolatyngol. 1980;5:195–211.

Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. Cancer staging handbooh from AJCC cancer staging mannual. 7th ed. New York: Springer; 2010. p. 39–126.

Samant S, Robbins KT, Vang M, Wan J, Robertson J. Intra-arterial cisplatin and concomitant radiation therapy followed by surgery for advanced paranasal sinus cancer. Arch Otolaryngol Head Neck Surg. 2004;130:948–55.

Kanoto M, Oda A, Hosoya T, Nemoto K, Ishida A, Nasu T, Koike S, Aoyagi M. Impact of superselective transarterial infusion therapy of high-dose cisplatin on maxillary cancer with orbital invasion. Am J Neuroradiol. 2010;31:1390–4.

Homma A, Sakashita T, Yoshida D, Onimaru R, Tsuchiya K, Suzuki F, et al. Superselective intra-arterial cisplatin infusion and concomitant radiotherapy for maxillary sinus cancer. Br J Cancer. 2013;109:2980–6.

Allal AS, Slosman DO, Kebdani T, Allaoua M, Lehmann W, Dulguerov P. Prediction of outcome in head-and-neck cancer patients using the standardized uptake value of 2-[18F]fluoro-2-deoxy-D-glucose. Int J Radiat Oncol Biol Phys. 2004;59:1295–300.

Tang C, Murphy JD, Khong B, La TH, Kong C, Fischbein NJ, et al. Validation that metabolic tumor volume predicts outcome in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 2012;83:1514–20.